Health

Molina Healthcare jumps 8% on a CMS work-rule delay; director Steven Orlando sold 702 shares at $227.33

A CMS work-rule delay bought Molina's Medicaid book time, not margin, and insiders including director Steven Orlando sold into the strength. New buyers are paying roughly 24 times a 2027 framework that is not yet guidance and must still be earned in February.

Richard TangRichard Tangthree-minute read
Share
Molina Healthcare brand mark: three teal figures beside the words Molina Healthcare
Molina Healthcare, which jumped 7.5% on November 16, 2026, after CMS let states delay Medicaid work-requirement enforcement.

Molina Healthcare−1.04% — Molina Healthcare, down 1.04 percent today jumped more than 8% to $226.47 intraday on Monday, November 16, and closed up 7.5% at $225.25, ahead of Centene−1.35% — Centene, down 1.35 percent today and Elevance, after the Centers for Medicare and Medicaid Services (CMS), the federal agency that runs Medicaid, let states shield Medicaid members from work-requirement denials through June 30, 2027 12.

The people who know the company best used the bounce to sell. Director Steven Orlando sold 702 shares at $227.33 that day, on a Form 4, the SEC filing an insider must submit after a trade, with no 10b5-1 plan, the preset selling schedule that would make the timing automatic rather than chosen 4. Chief legal officer Jeff Barlow sold $1.62 million of stock on November 10 at around $203, and director Dale Wolf sold $329,792 on November 13 at about $206 56.

Two directors and the chief legal officer sold $2.1 million of Molina stock in a week

$0K$500K$1,000K$1,500K$2,000KBarlow (CLO), Nov 10$1,620KWolf (director), Nov 13$329.8KOrlando (director), Nov 16$159.6K
Data
Value
Barlow (CLO), Nov 10$1,620K
Wolf (director), Nov 13$329.8K
Orlando (director), Nov 16$159.6K
Shares sold by named Molina insiders, in thousands of dollars. Barlow sold $1.62 million at about $203 on November 10, Wolf sold $329,792 at about $206 on November 13, and Orlando sold 702 shares at $227.33 on the November 16 rally day, per the Form 4 filings and reports on them [4][5][6].4,5,6

The delay changes timing, not premium

The news that moved the tape is thinner than the price move. Under the guidance issued Friday, a state that opts in still assesses whether members meet work requirements but cannot deny applications or terminate coverage solely for failing them, and it must still move toward full implementation; states decide by December 11 whether to take the option 3.

That changes when members can be disenrolled, not how much premium per member Molina collects 2. Chief financial officer Mark Keim still expects work rules and twice-yearly eligibility checks to cut Molina's Medicaid membership about 6% in 2027, and the third-quarter medical cost ratio stands at 92.9%, where each 100 basis points is worth roughly $5 a share 2. A six-month reprieve is timing relief, not margin repair.

Molina's operating margin has fallen to 1% from 4.5% in two years

-2%0%2%4%6%Q3 '24Q1 '25Q3 '25Q1 '26Q3 '261%
Data
Operating margin
Q2 '244.4%
Q3 '244.5%
Q4 '243.6%
Q1 '253.9%
Q2 '253.3%
Q3 '251.2%
Q4 '25-1.4%
Q1 '260.8%
Q2 '261.3%
Q3 '261%
Molina Healthcare operating margin, percent of revenue, by quarter, Q2 2024 to Q3 2026. Source: Molina's quarterly figures from its SEC filings [9].9

Four dollars of the $9.50 has to show up in February

The stock now trades around 24 times Keim's "at least $9.50" 2027 framework, which he explicitly called a framework rather than guidance, and about 43 times the $5.25 2026 adjusted earnings floor 2.

The $9.50 is built as $5.25 plus $4 of named repairs: $1.50 from bringing the new Florida CMS Kids contract to breakeven, $1.00 from exiting the general-issue Medicare Advantage product, and $1.50 from administrative leverage as premium grows toward $45 billion 2. It assumes no improvement in the Medicaid cost ratio, so every dollar of the $4 has to show up in February guidance 2. The shares also sit above the $219.53 average analyst target on a Hold rating 2, and Baupost, Seth Klarman's fund, had already trimmed its stake to about 450,000 shares from 634,000 in the third quarter, before the rally 7.

Four dollars of the $9.50 2027 framework is repairs Molina still has to earn

  • 2026 adjusted EPS floor5.2556.8%
  • Florida CMS Kids to breakeven1.516.2%
  • Exit general-issue Medicare Advantage110.8%
  • Administrative leverage on premium1.516.2%
Data
SliceValueShare
2026 adjusted EPS floor5.2556.8%
Florida CMS Kids to breakeven1.516.2%
Exit general-issue Medicare Advantage110.8%
Administrative leverage on premium1.516.2%
How Molina builds CFO Mark Keim's "at least $9.50" 2027 framework, dollars per share, as laid out in third-quarter commentary [2]. Neither the Florida repair nor the administrative leverage is in guidance yet.2

The filings say less than the rally story does

Barron's notes the new Democratic majority in Congress could extend the delays further; that is the outlet's speculation, not a decision anyone has made 8.

What the filings state is narrower: two directors and the chief legal officer sold within a week, one at $227.33 on the rally day itself with no preset plan, and every sale price sat at or above the consensus target 456. That does not prove anything about value, and it may be routine diversification. It does say the sellers were willing to take today's price. February guidance is where the framework gets tested: it either earns the $4 or breaks it, and a policy memo does not earn it for them 456.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading MOH

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    OpenAI prices healthcare back-office work at 8.5 cents a task, undercutting Ambience Healthcare

    OpenAI's new healthcare agents run prior-authorization work at 8.5 cents a task, and Menlo Ventures says the scribe market's new dollars are going to Microsoft and Epic. Ambience's $37,500-per-doctor receipt is now the only thing it sells that the model layer does not.

    Health

    Apple's 200,000-person health AI study runs on OpenEvidence with no disclosed price

    The 200,000-person study hands a $15 billion, ad-funded startup its first consumer channel, with no fee, equity or contract disclosed, and the closest public test of whether that free AI model is eating paid clinical reference lands in Wolters Kluwer's February results.

    Health

    Globus Medical director Tobin sold his entire stake for $3.1 million five days after a guidance cut

    James Tobin's November 10 sale left him with zero shares and zero options in Globus Medical, with no trading plan, five days after the company cut its 2026 revenue outlook by up to $130 million. The board's answer was a $500 million buyback increase.

    Health

    Molina Healthcare's CFO lays out a path to $9.50 EPS in 2027, on $4 of fixes not yet earned

    Molina's finance chief added $4 of "embedded earnings" to a $5.25 floor for 2027, assuming no recovery at all in Medicaid margins. Guidance, and the test of each dollar, arrives in February.

    Health

    Hims & Hers grew revenue 49% to $890 million, lost $33 million, and cut its 2026 profit outlook a third time

    Revenue grew 49% and the quarter still lost money, because selling Lilly's and Novo's branded weight-loss drugs books the full price without keeping it. Hims shareholders are paying for the pivot; Lilly gains a channel it barely needs.

    Health

    ACP licenses its guidelines to OpenEvidence for an undisclosed price

    The largest US medical society's guidance moves into a free, ad-funded AI valued at $15 billion, and neither side named the fee. For listed readers, the test is Wolters Kluwer's UpToDate renewals at February 2027 results.

    Subscribe to TheInference for free